Wasatch Advisors Inc. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 68.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 26,368 shares of the company’s stock after selling 56,436 shares during the period. Wasatch Advisors Inc.’s holdings in Johnson & Johnson were worth $3,684,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its stake in Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after purchasing an additional 3,023,110 shares during the last quarter. BlackRock Inc. raised its stake in Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after purchasing an additional 4,332,612 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Johnson & Johnson by 0.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after purchasing an additional 130,437 shares during the last quarter. FMR LLC raised its stake in Johnson & Johnson by 5.9% in the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after purchasing an additional 1,509,745 shares during the last quarter. Finally, Capital World Investors raised its stake in Johnson & Johnson by 4.1% in the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after purchasing an additional 1,050,000 shares during the last quarter. 67.23% of the stock is owned by institutional investors and hedge funds.
JNJ has been the subject of several recent research reports. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a research note on Monday, January 22nd. Vetr downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 price objective for the company. in a research note on Monday, March 26th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Wells Fargo reissued an “outperform” rating and issued a $160.00 price objective (up from $155.00) on shares of Johnson & Johnson in a research note on Friday, January 12th. Finally, Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $144.43.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. The business had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The company’s revenue was up 11.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.58 EPS. equities analysts expect that Johnson & Johnson will post 8.11 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th were issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.62%. The ex-dividend date of this dividend was Monday, February 26th. Johnson & Johnson’s dividend payout ratio is presently 46.03%.
In other news, VP Paulus Stoffels sold 155,342 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the transaction, the vice president now directly owns 357,906 shares in the company, valued at approximately $46,477,673.16. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.22% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.wkrb13.com/2018/03/31/johnson-johnson-jnj-shares-sold-by-wasatch-advisors-inc.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.